Biosimilars Part 1: History and Biology

(18:)

Biosimilars Part 2: Regulatory and Current Status

(13:25)

Biosimilars: Part I | Colby Evans, MD | USA

(4:43)

Biosimilars: Part II | Colby Evans, MD | USA

(10:26)

CADTH Webinar — Biologics and Biosimilars

(56:39)

Biosimilars Lunchtime Presentations, Part II

(10:36)

Biosimilars: A New Era of Gastroenterology Management Considerations (Part 1)

(1:7:28)

Biosimilars vs. Interchangeable Biosimilars: What’s the Difference?

(1:42)

Full Japan lecture uncut (English)

(50:6)

Biosimilars: Manufacturing and Inherent Variation

(3:33)

Biosimilars: A New Era of Gastroenterology Management Considerations (Part 2)

(1:5:25)

Biosimilars and Interchangeables - Regulatory Highlights (27of33) Quality – Oct. 16-17, 2019

(14:31)

Joe Glajch on Biosimilars Part 1: Analytical Methods

(7:46)

How similar are Biosimilars to Biologics? Part I

(22:50)

Biosimilars: Costs and Insurance Coverage

(1:53)

Jim Koeller Discusses the Complexities of Multiple Biosimilars (Part 2)

(12:56)

How similar are Biosimilars to Biologics? Part 2 | Breaking Down Biosimilars

(19:51)

Cultivating a vibrant U.S. market for biosimilars: A conversation with FDA’s Scott Gottlieb - Part 1

(49:42)

Impact of Biosimilars in Canada Part 3: Where is the landscape headed?

(7:51)

Regulatory Pathway for Biosimilars

(14:19)